Global HER2 Antibodies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for HER2 Antibodies Market is presumed to reach the market size of nearly USD 17.07 Billion by 2032 from USD 10.02 Billion in 2023 with a CAGR of 6.1% under the study period 2024-2032.

HER2 antibodies constitute a form of targeted therapy employed in treating HER2-positive breast cancer, a breast cancer subtype characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. These antibodies bind to the HER2 receptors on cancer cells, blocking their signaling pathways and inhibiting cell growth and proliferation. By targeting HER2-positive cancer cells specifically, these antibodies help to selectively kill cancer cells while sparing normal cells, minimizing side effects. HER2 antibody therapies are often used in combination with chemotherapy or other targeted therapies to improve treatment outcomes & survival rates among patients with HER2-positive breast cancer.

MARKET DYNAMICS

The increasing prevalence of HER2-positive breast cancer, a subtype of breast cancer featured by overexpression of the HER2 protein, is driving demand for targeted therapies such as HER2 antibodies. HER2-positive breast cancer accounts for a significant proportion of breast cancer cases globally, necessitating the development of effective treatment options to improve patient outcomes. Additionally, advancements in molecular diagnostics and biomarker testing have enabled healthcare providers to detect patients likely to benefit from HER2-targeted therapies, further driving market growth. Moreover, introducing novel HER2 antibodies with improved efficacy, safety, and tolerability profiles expands treatment options for patients with HER2-positive breast cancer, driving market growth.

Furthermore, collaborations between pharmaceutical companies, research institutions, and healthcare organizations drive innovation in HER2 antibody development, resulting in the discovery of new therapeutic targets and combination therapies. Additionally, regulatory approvals and reimbursement policies supporting the use of HER2 antibodies in treating breast cancer are driving market expansion and accessibility. However, advancements in targeted therapies and alternative treatment options may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of HER2 Antibodies. The growth and trends of HER2 Antibodies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the HER2 Antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Drugs

Trastuzumab
Lapatinib
Ado-trastuzumab Emtansine
Pertuzumab
Everolimus

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the HER2 Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the HER2 Antibodies market include Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Abnova Corporation, InvivoGen, Celltrion Inc., Biocon, Novus Biologicals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114433

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. HER2 ANTIBODIES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Drugs
- 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL HER2 ANTIBODIES MARKET ANALYSIS BY TREATMENT DRUGS

5.1. Overview By Treatment Drugs
5.2. Historical and Forecast Data
5.3. Analysis By Treatment Drugs
5.4. Trastuzumab Historic and Forecast Sales By Regions
5.5. Lapatinib Historic and Forecast Sales By Regions
5.6. Ado-trastuzumab Emtansine Historic and Forecast Sales By Regions
5.7. Pertuzumab Historic and Forecast Sales By Regions
5.8. Everolimus Historic and Forecast Sales By Regions

6. GLOBAL HER2 ANTIBODIES MARKET ANALYSIS BY GEOGRAPHY

6.1. Regional Outlook
6.2. Introduction
6.3. North America Sales Analysis
- 6.3.1 Overview, Historic and Forecast Data Sales Analysis
- 6.3.2 North America By Segment Sales Analysis
- 6.3.3 North America By Country Sales Analysis
- 6.3.4 United States Sales Analysis
- 6.3.5 Canada Sales Analysis
- 6.3.6 Mexico Sales Analysis
6.4. Europe Sales Analysis
- 6.4.1 Overview, Historic and Forecast Data Sales Analysis
- 6.4.2 Europe By Segment Sales Analysis
- 6.4.3 Europe By Country Sales Analysis
- 6.4.4 United Kingdom Sales Analysis
- 6.4.5 France Sales Analysis
- 6.4.6 Germany Sales Analysis
- 6.4.7 Italy Sales Analysis
- 6.4.8 Russia Sales Analysis
- 6.4.9 Rest Of Europe Sales Analysis
6.5. Asia Pacific Sales Analysis
- 6.5.1 Overview, Historic and Forecast Data Sales Analysis
- 6.5.2 Asia Pacific By Segment Sales Analysis
- 6.5.3 Asia Pacific By Country Sales Analysis
- 6.5.4 China Sales Analysis
- 6.5.5 India Sales Analysis
- 6.5.6 Japan Sales Analysis
- 6.5.7 South Korea Sales Analysis
- 6.5.8 Australia Sales Analysis
- 6.5.9 South East Asia Sales Analysis
- 6.5.10 Rest Of Asia Pacific Sales Analysis
6.6. Latin America Sales Analysis
- 6.6.1 Overview, Historic and Forecast Data Sales Analysis
- 6.6.2 Latin America By Segment Sales Analysis
- 6.6.3 Latin America By Country Sales Analysis
- 6.6.4 Brazil Sales Analysis
- 6.6.5 Argentina Sales Analysis
- 6.6.6 Peru Sales Analysis
- 6.6.7 Chile Sales Analysis
- 6.6.8 Rest of Latin America Sales Analysis
6.7. Middle East & Africa Sales Analysis
- 6.7.1 Overview, Historic and Forecast Data Sales Analysis
- 6.7.2 Middle East & Africa By Segment Sales Analysis
- 6.7.3 Middle East & Africa By Country Sales Analysis
- 6.7.4 Saudi Arabia Sales Analysis
- 6.7.5 UAE Sales Analysis
- 6.7.6 Israel Sales Analysis
- 6.7.7 South Africa Sales Analysis
- 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE HER2 ANTIBODIES COMPANIES

7.1. HER2 Antibodies Market Competition
7.2. Partnership/Collaboration/Agreement
7.3. Merger And Acquisitions
7.4. New Product Launch
7.5. Other Developments

8. COMPANY PROFILES OF HER2 ANTIBODIES INDUSTRY

8.1. Top Companies Market Share Analysis
8.2. Market Concentration Rate
8.3. Novartis AG
- 8.3.1 Company Overview
- 8.3.2 Company Revenue
- 8.3.3 Products
- 8.3.4 Recent Developments
8.4. Pfizer Inc.
- 8.4.1 Company Overview
- 8.4.2 Company Revenue
- 8.4.3 Products
- 8.4.4 Recent Developments
8.5. F. Hoffmann-La Roche Ltd.
- 8.5.1 Company Overview
- 8.5.2 Company Revenue
- 8.5.3 Products
- 8.5.4 Recent Developments
8.6. Abnova Corporation
- 8.6.1 Company Overview
- 8.6.2 Company Revenue
- 8.6.3 Products
- 8.6.4 Recent Developments
8.7. InvivoGen
- 8.7.1 Company Overview
- 8.7.2 Company Revenue
- 8.7.3 Products
- 8.7.4 Recent Developments
8.8. Celltrion Inc.
- 8.8.1 Company Overview
- 8.8.2 Company Revenue
- 8.8.3 Products
- 8.8.4 Recent Developments
8.9. Biocon
- 8.9.1 Company Overview
- 8.9.2 Company Revenue
- 8.9.3 Products
- 8.9.4 Recent Developments
8.10. Novus Biologicals
- 8.10.1 Company Overview
- 8.10.2 Company Revenue
- 8.10.3 Products
- 8.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies